Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500.
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
providing valuable ballast to Gilead's portfolio. Earlier this year, Gilead acquired the liver disease-focused biotech Cyma Bay in a deal worth ~$4.3bn, giving it access to seladelpar, now ...
Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseases. While the drug candidates ...
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
While the Gilead pipeline has promise, the HIV portfolio of drugs has generated the most robust results. It was determined to exit the position as the pipeline timeline has been pushed out.
Through this agreement, Gilead will gain access to Tubulis ... “As we expand our oncology portfolio to address the greatest gaps in care, accessing novel technologies is critical to advancing ...
The article discusses six major constituents of the Invesco Pharmaceuticals ETF PJP: Pfizer, Amgen, Gilead Sciences, AbbVie, Bristol-Myers Squibb, and Merck & Co. The focus lies on the ...
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...